Concord Biotech Limited (CONCORDBIO)
Solvency Rating
Score: 90/100
Debt Overview
| Total Debt | ₹97376000.0 |
| Total Equity | ₹0 |
| Debt to Equity | 0 |
| Interest Coverage | 162.67x |
Liquidity Ratios
| Current Ratio | 6.3 |
| Quick Ratio | 4.84 |
| Cash Ratio | 0.11 |
| Working Capital | ₹7540757000.0 |
Key Solvency Indicators
Debt/Equity
0
Current Ratio
6.3
Interest Coverage
162.67x
Quick Ratio
4.84
Solvency Analysis Score: 90/100
Solvency Score: 90/100
Key Financial Indicators:
- Excellent debt management with D/E ratio below 0.5
- Strong liquidity with current ratio above 2
- Strong ability to meet interest payments
- Excellent quick ratio above 1.5
- Positive working capital position
Recommendation
Strong Financial Health - Company shows excellent solvency and liquidity metrics
Detailed Analysis
Debt Management: D/E ratio of 0.00 indicates conservative use of leverage.
Liquidity: Current ratio of 6.30 shows strong short-term solvency.
Interest Coverage: 162.67x coverage indicates excellent ability to service debt.
Quick Position: Quick ratio of 4.84 demonstrates strong immediate liquidity.
Risk Assessment Guide
- Score 80-100: Low risk profile with strong financial stability
- Score 60-79: Moderate risk with good financial management
- Score 40-59: Elevated risk, monitor financial metrics closely
- Score Below 40: High risk, significant financial concerns present
Key Metrics
- Working Capital: ₹754.1Cr
- Cash Ratio: 0.11
- Total Debt: ₹9.7Cr
Last Updated: 2025-01-23 06:42:28